Pertuzumab biosimilar (Qilu Pharmaceutical)

Product Name :
Pertuzumab biosimilar (Qilu Pharmaceutical)

Search keywords :
Pertuzumab

drugId :
null

Target Vo:
Receptor protein-tyrosine kinase erbB-2

Target Vo Short Name :
HER2

Moa_Name:
Receptor protein-tyrosine kinase erbB-2 antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Qilu Pharmaceutical Co Ltd

Active Company_Name :
Qilu Pharmaceutical Co Ltd

Active Indication_Name:
Breast Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
NDA/BLA

China Highest Status:
NDA/BLA

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Lipocalin 2 Antibody (YA992) manufacturer
PARP2 Rabbit mAb Data Sheet
AIF Antibody (YA835): AIF Antibody (YA835) is a non-conjugated and Mouse origined monoclonal antibody about 67 kDa, targeting to AIF (8H1). It can be used for WB,ICC/IF assays with tag free, in the background of Human.

Author: Betaine hydrochloride

Related Posts